Oncodesign SA

Oncodesign SA is a France-based company that discovers and develops therapies against cancer. The Company's services include target identification, validation and cellular screens; preclinical research, in vivo screening and pharmacology; molecular pharmacology and biomarkers, pharmaco-imaging and immunology, among others. Its activities include preclinical evaluation services and discovery operations. The Company's technologies include Predict, Chi-Mice, Pharm'Image and Nanocyclix. Its technological platform offers solutions for pharmaceutical and biotechnology companies.
  • TickerA1107T
  • ISINFR0011766229
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Gilbert Ferrand

ONCODESIGN SA. Net results H1 2018. Balance sheet and operating result under control

ONCODESIGN SA. Net results H1 2018. Balance sheet and operating result under control

Gilbert Ferrand

ONCODESIGN SA. Net results H1 2018. Balance sheet and operating result under control

ONCODESIGN SA. Net results H1 2018. Balance sheet and operating result under control

Gilbert Ferrand

ONCODESIGN SA. RN S1 2018. Bilan et soldes de gestion maîtrisés

ONCODESIGN SA. RN S1 2018. Bilan et soldes de gestion maîtrisés

Gilbert Ferrand

ONCODESIGN SA. Turnover H1 2018. Strong dynamics in services

The group has announced revenues (excluding CIR) of €13.2M for the first half of 2018, up 35%; these comprise €8.66M from service activities (€5.31M in H1 2017), up 21.4% at constant scope (excluding Bertin Pharma taken over in September 2017), €0.57 from Partnership business (vs €0.51M in H1 2017) corresponding to the reimbursement of the expenses incurred by Oncodesign in the framework of Drug Discovery underway with UCB and Bristol-Myers Squibb, and an item of other revenues including the subsidies paid by GSK (€3.96M pro rata over 6 months, stable compared to H1 2017) within the François H...

Gilbert Ferrand

ONCODESIGN SA. CA S1 2018. Forte dynamique en services

Le groupe annonce des produits d'exploitation (hors CIR) de 13,2 M€ au titre du premier semestre 2018, en hausse de 35% ; ces produits se composent de 8,66 M€ de CA issus des activités de services (5,31 M€ en S1 2017), en hausse de 21,4% à périmètre constant (hors les activités Bertin Pharma reprises en septembre 2017), de 0,57 M€ de CA réalisé en Partenariat (vs 0,51 M€ au S1 2017) correspondant au remboursement des frais engagés par Oncodesign dans le cadre des collaborations de Drug Discovery en cours avec UCB et Bristol-Myers Squibb, et d’un poste d’autres revenus constitués des subvention...

Gilbert Ferrand

ONCODESIGN. A financial year of in-depth transformation

ONCODESIGN’s 2017 annual accounts are marked by the in-depth transformation and restructuring of the group carried out over the last 18 months.

Insider sold: A director sold 93,100 shares at 18.203EUR and

A director at Oncodesign sold 93,100 shares at 18.203EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Etude de l'AG du 29/06/2017

Da façon générale, la communication de la société est plutôt basique, voire lacunaire puisque la description du conseil est assez parcellaire (absence de communication des dates de début et de fin de mandats), de même que la communication des honoraires des commissaires aux comptes (la société se contente de communiquer un montant global sans en préciser la répartition entre chacun des commissaires ou la répartition entre les différents postes de facturation). De plus, la communication sur les rémunérations des dirigeants est nulle : la société se contente d'indique que communiquer les montan...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch